The United States Therapeutic Apheresis Market to Reach US$120 Million by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive report on the US Therapeutic Apheresis market. The US therapeutic apheresis market is forecast to reach US$120 Million by 2015, driven by emerging applications in autoimmune diseases, refractory chronic GvHD, lupus erythematosus, hyperlipidemia, atherosclerosis, and renal diseases. Other factors that are expected to drive market growth include growing research for new technology, innovative products, and novel applications. The untapped pediatric segment is likely to present potential opportunity to expand the therapeutic apheresis market.

Therapeutic Apheresis: A US Market Report

Growth of therapeutic apheresis market is driven by photopheresis, which is growing at a rapid pace. Erythrocytapheresis and Plateletpheresis are the other significant procedures, which are gaining impetus in the matured therapeutic apheresis market. With burgeoning photopheresis, and much-preferred plateletpheresis procedures, therapeutic apheresis is all set to witness rapid growth in the coming years. Increased adoption of this therapy would also be backed by the customized reimbursement policies by medical insurers as per different disease needs. Besides, medical insurers are also poised to expand the coverage of reimbursement policies to other chronic diseases. Usage of pathogen reduction technology is another factor driving the therapeutic apheresis market. Research is underway, adding new dimensions to the market and unveiling newer sophisticated applications. Technology is another key factor bolstering volume growth.

The US therapeutic apheresis market is poised to witness healthy growth over the coming years, as stated by the new market research report on Therapeutic Apheresis. Photopheresis constitutes the largest therapeutic apheresis procedure in terms of revenues. The procedure is also forecast to witness the fastest growth, registering a compounded annual growth rate of 9.2% during the analysis period. Robust growth of photopheresis is attributable to its growing demand in off-label indications such as prevention of solid organ transplant rejection, and treatment of Graft-Versus-Host Disease (GVHD). Plasmapheresis is the second largest segment, followed by erythrocytapheresis.

In terms of end-use, hematology and oncology is the single-largest market for therapeutic apheresis. Rheumatology represents the fastest growing end-use market for therapeutic apheresis, registering a CAGR of 6.29% over the analysis period. Technology plays a vital role in boosting volumes of growth in the matured therapeutic apheresis market. As competition is spicing up, players are keen to develop advance technologies in order to have a competitive edge. Market alliances and agreements are the buzzwords in the therapeutic apheresis market. Through agreements and partnerships, companies are conducting research to develop technologically advanced apheresis instruments, and novel procedures to expand the coverage of therapeutic apheresis to other chronic diseases. With growing competition, numerous companies in the US are vigorously involved in R&D and marketing activities of therapeutic apheresis.

Key players profiled in the report include CaridianBCT Inc., Fenwal Inc., Fresenius Medical Care North America (FMCNA), Haemonetics Corp., HemaCare Corp., Hospital Clinical Services Group Inc., Therakos, Inc., among others.    

The report titled “Therapeutic Apheresis: A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of therapeutic apheresis, current market trends, growth drivers, opportunities, different types of procedures, end-use market analysis, product and technological developments, recent industry activity, profiles of major market participants. The report analyzes market data and analytics in terms of value for the United States. Key procedures analyzed include Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. The report also analyzes major application areas, including Neurology disorders, Hematology and oncology disorders, Rheumatology disorders, and Others.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Therapeutic_Apheresis_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media